Fresenius Kabi AG / Akorn, Inc.

Specialty Generic Pharmaceuticals (Injectable, Ophthalmic, Topical)

$31.3B Global specialty injectable generics market 2017

Disease Overview

Specialty generic pharmaceuticals — sterile injectables, ophthalmic solutions, and topical formulations — occupy a hard-to-manufacture niche of the broader generics market. Higher technical barriers (sterile fill-finish, complex formulations) historically protected this category from the price erosion that hit oral solid-dose generics, attracting strategic acquirers seeking margin-resilient growth.

Competitive Landscape

The 2017 specialty generics injectables market was led by Pfizer's Hospira franchise (acquired 2015), Sandoz (Novartis), Mylan, Hikma, Teva, and Fresenius Kabi itself. Akorn's $1.1B revenue base — with sterile injectables at ~35% of the mix and a strong ophthalmic franchise — was viewed as strategically complementary to Fresenius Kabi's existing US injectables platform. The $4.75B deal (announced April 2017) would have ranked as one of the largest specialty-generics acquisitions of the decade. The transaction collapsed after anonymous whistleblower letters in late 2017 alleged FDA data integrity breaches at Akorn manufacturing sites; Fresenius's independent investigation found 'extensive and recurring' problems including fabricated regulatory filings. Fresenius terminated April 2018, and on October 1, 2018 the Delaware Court of Chancery in Akorn v. Fresenius Kabi found a Material Adverse Effect — the first MAE finding in Delaware history — and upheld termination. Akorn ultimately filed Chapter 11 in 2020.